Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's Combo Product Consultations To Be Streamlined

This article was originally published in The Pink Sheet Daily

Executive Summary

Internal assessment finds inter-center collaboration stymied by issues ranging from IT compatibility to resource reimbursement, but FDA says it has a five-point plan to improve the process.

You may also be interested in...

Combo Product Safety: US FDA Rule On Postmarket Reporting Nears Finalization

Industry is eagerly awaiting guidance on combination products, and after seven years the postmarketing reg may be at top of the agency’s queue.

FDA 'Intercenter Institutes' Legislation Headed For Senate Mark-Up

FDA would be directed to test the concept of joint drug/device/diagnostic reviews in at least one therapeutic area; idea of further integrating medical product reviews is also part of Vice President’s cancer 'moonshot.'

Califf Supports Combo Products Pathway At Confirmation Hearing

FDA's concepts for new pathway could be ready for congressional scrutiny within a year.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts